The urokinase plasminogen activator receptor as a gene therapy target for cancer

Full text for this resource is not available from the Research Repository.

Pillay, Vinochani, Dass, Crispin R and Choong, Peter F. M (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends in Biotechnology, 25 (1). pp. 33-39. ISSN 0167-7799


Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. Impairment of uPA and/or uPAR function, or inhibition of the expression of these components, impedes the metastatic potential of many tumours. Several approaches have been employed to target uPAR with the aim of disrupting its ligand-independent action or interaction with uPA, including the more recent antigene technology. This review discusses the in vivo use of antigene approaches for downregulating uPAR as a potential therapy for cancer. Preclinical studies are advancing towards the translational phase, provided that established orthotopic tumours, which mimic clinical progression and presentation, are treated using clinically acceptable modes of nucleic acid delivery.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.1016/j.tibtech.2006.10.011
Official URL
Subjects Historical > FOR Classification > 1112 Oncology and Carcinogenesis
Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Keywords ResPubID18875, Urokinase plasminogen activator (uPA) and/or its receptor (uPAR), metastasis, malignant tumours, uPAR function, antigene technology, therapy for cancer, nucleic acid delivery
Citations in Scopus 102 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login